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Abstract
Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal b-oxidation of phytol-derived, branched-chain
fatty acids from red meat and dairy products — suspected risk factors for colon carcinoma (CCa). AMACR was first found
overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
Aberrant expression of AMACR was recently reported in Cca; however, little is known about how this gene is abnormally
activated in cancer. By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire
colon adenoma–carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two
nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-
16 in a newly identified CpG island within the core promoter of AMACR. The double-deletion at CG3 and CG10 was found to
be a somatic lesion. It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression
and was absent in villous adenomas and all CCas expressing variable levels of AMACR. In contrast, deletion of CG12-16 was
shown to be a constitutional allele with a frequency of 43% in a general population. Its prevalence reached 89% in
moderately differentiated CCas strongly expressing AMACR but only existed at 14% in poorly differentiated CCas expressing
little or no AMACR. The DNA sequences housing these deletions were found to be putative cis-regulatory elements for Sp1
at CG3 and CG10, and ZNF202 at CG12-16. Chromatin immunoprecipitation, siRNA knockdown, gel shift assay, ectopic
expression, and promoter analyses supported the regulation by Sp1 and ZNF202 of AMACR gene expression in an opposite
manner. Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas
and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
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Introduction
Alpha-methylacyl-CoA racemase (AMACR) is a peroxisomal
and mitochondrial enzyme that is indispensable in the catabolism
of phytol-derived, 2-methyl-branched-chain fatty acids and the
synthesis of bile acids [1]. In hepatocytes, AMACR catalyzes the
conversion of pristanoyl-CoA and C27-bile acyl-CoAs from R- to
S-stereoisomers, which are the only stereoisomers that can
undergo b-oxidation. Bile acid intermediates undergo one round
of b-oxidation in the peroxisomes and are secreted. In contrast,
branched-chain fatty acid derivatives are transported to mito-
chondria, where they are further degraded to generate biological
energy. Since most malignancies increase fatty acid utilization as
an energy source to fuel growth [2], it has been suggested that
increased b-oxidation of branched-chain fatty acids provides
transformed cells with a unique metabolic advantage [3]. This idea
is supported by recent findings that knockdown of AMACR
transcripts or inhibition of the racemase activity effectively blocked
growth of prostate cancer (PCa) cells [4,5]. In humans, the major
sources of phytol-derived, 2-methyl-branched fatty acids are
dietary ruminant fats, meat, and dairy products. Increased
consumption of these foods are known risk factors for prostate
and colon carcinoma (CCa) [6,7].
Aberrant expression of AMACR was first reported in PCa and
high-grade prostatic intraepithelial neoplasia but not in benign
hyperplastic lesions or normal epithelia [8,9]. These findings
quickly led to the establishment of AMACR as a reliable
diagnostic marker for PCa [10–13]. More recently, overexpression
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between 45% and 75% [19–21]. However, the relationship
between levels of AMACR expression and the sequence of
adenoma-carcinoma progression in the colon [22] has not been
fully characterized. Except for a report that identified a non-
canonical CCAAT enhancer element in the AMACR promoter [5]
and a lack of regulation of this gene by androgen [16,23], no
information is available regarding how the AMACR gene is
regulated. Furthermore, although recent studies have identified a
few AMACR gene variants to be associated with PCa [24,25] or
CCa [26] risks, a sequence polymorphism in the promoter region
of AMACR has not been reported.
Given the potential significance of AMACR in CCa, our
objectives in this study were to determine the mechanisms of
AMACR gene regulation in vivo during neoplastic transformation of
the colon epithelium. Through the use of a comprehensive panel
of immunostained-laser-capture-microdissected (iLCM) clinical
samples comprising the entire colon adenoma-carcinoma se-
quence, we now report that the deregulation of AMACR during
colon carcinogenesis involves non-random events, resulting in a
double-deletion at CG3 and CG10, and alterations in the
frequencies of deletion of CG12-16 in a newly identified CpG
island (CGI) located within the core promoter of AMACR. We also
identified deletion of CG12-16 as a putative regulatory polymor-
phism and the double-deletion at CG3 and 10 as a somatic lesion.
The DNA sequences housing these deletions were indicated to be
a cis-regulatory element for Sp1 and a putative ZNF202-binding
site, respectively, and to exert opposite effects on AMACR
transcription.
Results
Overexpression of AMACR in Villous Adenomas and in
Well- and Moderately Differentiated CCas but not in
Poorly Differentiated CCas
We first provided a detailed description of the relationship
between AMACR expression levels and the sequence of adenoma-
carcinoma progression in the colon. The levels of AMACR in 55
foci representing seven normal, premalignant and malignant
histological entities in 35 colon specimens were semiquantified in
immunostained slides (Figure 1A to 1H). These foci were
subsequently microdissected for AMACR promoter studies. In
general, AMACR immunostaining was negative to weak in normal
cryptal (Figure 1A) and apical (Figure 1B) epithelia, as well as in
tubular adenomas (TAs) with mild dysplasia (Figure 1C). In
contrast, villous adenomas (VAs) (Figure 1D), well- (Figure 1E and
1F) and moderately (Figure 1G) differentiated adenocarcinomas
expressed high levels of AMACR. AMACR immunostaining was
almost absent to negligible in poorly differentiated carcinomas
(Figure 1H). Compared with the expression in normal crypt, levels
of AMACR expression, represented as a score of 0 to 4, were
significantly increased in VAs and in well- and moderately
differentiated carcinoma but not in normal apex, TAs, and poorly
differentiated carcinoma (Figure 1I).
Organization of the AMACR Proximal Promoter Region
Because virtually no information is available on how AMACR is
regulated in vivo, we initially were interested in determining if
changes in DNA methylation status of the AMACR 59 flanking
promoter region play a role in gene regulation. In silico analysis
revealed that AMACR transcripts share the same first exon with an
88-bp 59 untranslated region (59 UTR), suggesting that the gene is
controlled by one promoter. Two CGIs were identified flanking
the transcription start site (Figure 2A). The first is a novel CGI
located upstream of the ATG site (2230 to 260; the position of
the translation start site was set as +1) with 18 CG dinucleotides,
whereas the second CGI downstream of the ATG site (48 to 357,
not shown in Figure 2A) has been reported and shown to not be
involved in gene regulation in PCa cells [5]. In concordance, our
pilot studies indicated that the downstream CGI exhibited no
differences in methylation/deletion/mutation status among the
histological entities of the colon (data not shown). Hence,
subsequent studies were focused on analyses of the previously
not reported proximal CGI in the AMACR promoter region (the
AMACR promoter CGI). Our bisulfite sequencing data did not
support the involvement of DNA methylation of this newly
identified CGI in AMACR gene regulation in vivo, since the
promoter is largely unmethylated in all 55 iLCM samples (next
section). However, in silico analyses identified two putative Sp1
binding sites at CG3 and CG10 and a non-canonical ZNF202 [27]
cis-element at CG12-16 of this CGI (Figure 2B). Variable
frequencies of deletions were found at these sites and later shown
to be involved in gene regulation (next section). A previously
reported non-canonical CCAAT enhancer element [5] was
aligned to CG5. Two direct repeat sequences, 7 bp in length,
were noted to flank the transcription start site. We later proposed
that these two repeated sequences are involved in the generation of
the CG12-16 deletion (dotted lines; see Discussion below).
Identification of Deletion Hotspots in the Novel AMACR
Promoter CGI in Colon Tissues
A 222-bp region encompassing all 18 CG sites in the newly
identified AMACR promoter CGI (Figure 2) was analyzed for
methylation, deletion, and mutation changes using DNA obtained
from LCM samples and CCa cell lines. Bisulfite sequencing
analyses of 239 alleles from 55 foci and regular DNA sequencing
of 37 alleles from 9 foci as the control (also see next section)
showed that most of the CG sites were unmethylated (Table 1).
However, variable frequencies of deletions, methylation, and
mutations were found to occur almost invariably at CG3, CG10,
and CG12-16, with deletions as the predominant lesion among all
aberrations. The sequences of these deletion and mutation variants
Author Summary
Men consuming high amounts of red meat and dairy
products are at a higher risk of developing colon and
prostate cancer. Alpha-methylacyl-coenzyme A racemase
(AMACR) is an enzyme that helps to break down fat from
these foods to produce energy. An increase in the
utilization of energy from fat is a hallmark of many cancers
including colon and prostate cancers. Indeed, the AMACR
gene was first found to be abnormally active in prostate
cancers, and its abnormal expression has become a
diagnostic marker for the cancer. However, little is known
about how AMACR becomes activated in cancer cells. Here,
we show that AMACR is also highly expressed in certain
stages of colon cancer, though not all stages. A close
examination of the AMACR gene in a panel of normal and
progressively malignant colon tissues reveals that dele-
tions of specific sequences in the AMACR gene may trigger
its abnormal expression during the evolution of colon
cancer. We also identify unique proteins known as
‘‘transcription factors’’ that normally bind to these deleted
sequences to maintain normal expression of the gene.
Finally, we report a new deletion variant of the AMACR
gene in the general population that may influence the
course of colon carcinogenesis.
Deletion Hotspots Regulate AMACR Promoter
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EF636492 to EF636496. Cluster analyses demonstrated that
deletion of CG12-16 was the most common co-occurrence,
followed by deletion at CG3 and CG10 (double-deletion at CG3
and CG10) (Figure 3A). Cluster analyses data for methylation
(Figure 3A), mutations (Figure S1), and all aberrations (Figure S1)
were also obtained. The number of deleted nucleotides (nts) was 2
to 8 nts at CG3 and 2 nts at CG10 (Figure 3B). Deletion at CG12-
16 was found to be precisely 20 nts. Among the four CCa cell lines
examined, CG12-16 deletions were found in SW480 and SW620;
no double-deletion of CG3 and 10 was detected in any of these cell
lines. Thus, while methylation of this novel CGI does not appear
to play a role in gene regulation, deletions of specific sequences or
deletion hotspots within this sequence were identified and might
play critical roles in the regulation of gene expression and/or the
adenoma-carcinoma progression.
Deletion Hotspots Are Not Due to Artifacts from Bisulfite-
Treatment, PCR or Sequencing
As our focus on promoter assay will be based on the above
sequencing results, we herein provide several pieces of data to
ensure that the deletions were not artifacts of bisulfite-treatment of
the DNA, PCR or sequencing. First, bisulfite modification reduced
the GC content to ,41% in the 222-bp AMACR promoter CGI,
which made the sequencing easier to read; second, visual
examination of sequencing chromatogram files showed clean
Figure 1. Detection of AMACR expression level by immunostaining. A–H: the typical AMACR immunostaining found in normal and
neoplastic colon sections from our case materials. I: AMACR expression scores of these foci, representing the above groups, depicted in a scatter plot.
One-way analysis of variance, followed by Tukey’s HSD post hoc test, indicated the significant difference among different groups (p,0.0001). The
normal crypt group served as a reference. Foci with normal cryptal glands had very low AMACR expression (score: 0.2260.22), with 8 of 9 foci scored
negative. Foci with normal apical surface epithelium had mildly elevated expression (1.160.55) that was not statistically different from that of the
former group (p=0.67). Expression at foci harboring TA glands with a mild degree of dysplasia (0.2260.15, p=1.00) was not statistically different from
that in normal cryptal glands. However, VAs had elevated expression (2.360.62, p=0.007) comparable to that of well- (2.860.60, p=0.001) and
moderately differentiated carcinomas (2.760.49, p=0.002); the three groups (open ellipses) have higher AMACR expression scores than normal and
TAs. In marked contrast, AMACR expression scores in poorly differentiated cancers were low (0.1460.14, p=1.00), with 6 of 7 foci devoid of AMACR
immunostaining.
doi:10.1371/journal.pgen.1000334.g001
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we observed in bisulfite sequencing were not due to a GC
compression artifact (Figure S2A). In addition, as an internal
control to ensure complete bisulfite modification, we routinely
examined and found that almost 100% of the non-CpG cytosines
in this region were converted to T, indicating complete bisulfite
modification.
To demonstrate that the CG12-16 deletion was not due to the
PCR artifact, we used sequencing-verified plasmids with or
without CG12-16 deletion as PCR templates, the PCR products
showed expected size with different positions in 3% agarose gel
(Figure S2B, left panel). Additionally, we used unmodified (not
shown) and bisulfite-treated genomic DNA, with or without the
CG12-16 deletion, as templates and performed multiple PCRs on
the same two samples (Figure S2B, right panel). Results
demonstrated the sizes of the amplicons derived from wild-type
and deletion-variant templates were consistent, indicating that the
deletion of CG12-16 was neither a PCR artifact nor a result of
bisulfite-treatment.
Blast searches provide additional evidence that the CG12-16
deletion exists in the human genome, as of the two genome
sequences, one is the reference assembly that corresponds to the
sequence (NT_006576.15) without CG12-16 deletion and the
other is the Celera assembly (NW_922562.1) exhibiting the
deletion, which exactly matches what we discovered in the
AMACR promoter in clinical samples (Figure S2C).
Finally, we conducted parallel bisulfite and regular sequencing
on DNA isolated from LCM-captured normal or malignant colon
epithelial cells from 9 colon specimens. Identical sequence results
were obtained with the two methods (data not shown). Thus, in
conclusion, these control experiments and in silico analyses
demonstrate that the observed deletion hotspots in this CGI exist
in colon tissues and are not results of artifacts generated from
bisulfite-treatment, PCR or sequencing.
Deletion of CG12-16 and Double CG3 and 10 Deletions
Are Mutually Exclusive Molecular Events that Appear to
Underlie AMACR Expression and CCa Development
We then investigated the relationship between deletion patterns
in the AMACR promoter CGI and levels of AMACR expression
(Table 2, left) in 55 iLCM samples to gain insight into how these
Figure 2. The organization of AMACR gene 59-flanking region. A: The location of the CpG island upstream translation start site (designated as
+1). Individual CG sites are indicated as red vertical lines and numbered from 1 to 18. The 222-bp nested PCR-amplified CGI is illustrated. B: Partial
exon 1 and the promoter sequence encompassing the CGI. The first exon is indicated by a bent arrow (TSS). Predicated transcription factor binding
sites of Sp1 and ZNF202, together with the CCAAT enhancer binding site, are underlined. The locations of two pairs of primers for bisulfite
sequencing PCR are blocked with different colors. The ChIP assay-amplified region is marked with brackets. The DNA upstream -4 (bent arrow,
promoter clone) was cloned for promoter analysis. Two direct repeats of up to 7 nt (59-GGCGCCG-39) that may related to the deletion caused by
slipped-strand mispairing are marked by dotted lines. Primers PolyF/PolyR for polymorphism study are marked with the arrows. The wild type (WT)
probe for gel shift assay targeting on putative ZNF202 binding site is boxed. Two short putative ZNF202 core sequences identified by MatInspector
were highlighted in red.
doi:10.1371/journal.pgen.1000334.g002
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were rather common (13–41%) but were not correlated with
AMACR expression, and CG10-only deletions were rare (0–5%).
However, double CG3 and 10 deletions occurred at higher
frequencies and invariably only in foci with no or little AMACR
expression (17–28%, scores 0 and 1). In contrast, CG12-16
deletions were common (21–67%) and showed a positive
correlation with the AMACR expression score. In total, foci with
moderate and high AMACR expression (scores 2–4) had a high
frequency of CG12-16 deletions (53–67%) and no double CG3
and 10 deletions.
Next, we examined the type of deletions found in the six
histological entities (Table 2, right) to determine their relationship
to the adenoma-carcinoma progression paradigm. CG3-only
deletions were commonly found among normal and CCa foci.
In most cases, GC10 deletions occurred as double CG3 and 10
deletions found in normal epithelium and TA (24–25%). In
contrast, the double-deletion was not identified in VA or in CCa of
any grade. CG12-16 deletions were found in all six histological
entities; however, their frequency markedly increased in well-
(56%) and moderately (89%) differentiated cancers and correlated
with high AMACR expression in these lesions (mean expression
Figure 3. Bisulfite sequencing analysis of iLCM. The results were summarized from the status of 4302 CG sites from a total of 239 alleles in the
entire set of 55 microdissected samples. A: Cluster analyses of the deletion and methylation to establish clusters of CG sites based on the entire
sequencing data set. The average linkage was employed for hierarchical clustering (sites 1–18). The absolute number of co-occurrences of different
CG deletions was used as the similarity measure. The higher the number of clones with two specific CG deletions, the closer they are in the
dendrogram. The hotspots were restricted to CG3, 10, and 12-16. B: Typical bisulfite sequencing results of AMACR CGI with deletions highlighted in
grey. The sequences of AMACR promoter variants have been deposited in Genbank and are described in Materials and Methods.
doi:10.1371/journal.pgen.1000334.g003
Table 1. Bisulfite sequencing analysis of iLCM samples.
CG site 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18
Deletion% 0.0 0.0 30 0.0 0.0 0.0 0.0 0.0 0.0 13 0.0 42 42 42 42 42 0.0 0.0
Mutation% 0.0 0.0 3.5 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0
Methylation% 1.2 1.6 5.6 0.0 0.4 1.4 0.5 0.7 0.0 1.5 1.7 0.0 1.6 1.6 1.6 0.0 0.8 1.6
Total% 1.2 1.6 39 0.0 0.4 1.8 0.5 0.7 0.0 15 1.7 42 44 43 44 42 0.8 1.6
Genetic (deletion and mutation) and epigenetic (methylation) changes in each CG site. Pronounced alternations of the CG hotspots are in bold. Genetic changes outside
the CG sites were rare and negligible (data not shown). Deletion, but not mutation or methylation, was the most commonly identified alteration.
doi:10.1371/journal.pgen.1000334.t001
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deletions of all kinds was low in poorly differentiated cancers; 72%
of these foci have no lesions in the AMACR promoter CGI. Like all
other CCas, they lack the deletion of CG3 and 10; the frequency
of CG12-16 deletion in these CCas was low (14%), which
correlates with negligible to low levels of AMACR expression in
these lesions (mean expression score ,0; Figure 1H). Compared
with the CG12-16 deletion in the moderately differentiated group
that has the highest deletion rate, statistic analysis indicated the
deletion was significantly changed in the normal, TA, VA and
poorly differentiated groups but not in the well differentiated
group.
Together these data showed an intriguing in vivo phenomenon.
Consistently, in all the samples analyzed, deletion of CG12-16 are
not co-existed with double CG3 and 10 deletions (frequency=0;
Table 2). Additionally, double-deletions at CG3 and 10 are found
only in normal epithelium and TA and are not observed in VA
and CCa of all grades. In contrast, CG12-16 deletions are
associated with moderate and well differentiated CCa that express
high AMACR but not in poorly differentiated cancers that show
negligible AMACR expression. These findings provide the
impetus for a study of the effects of these deletions on AMACR
transcription an in vitro system (the HCT 116; see below).
Deletion of CG12-16 Is a Polymorphism But the Deletions
at CG3 and CG10 Are Somatic Lesions
To better understand the relevance of these deletions to colon
carcinogenesis, we must ask if these deletions are results of genetic
events occurring in somatic cells of the colon or are constitutional
alleles exist in the general population. Before this study, the only
information available is that a sequence (NW_922562.1) harboring
the CG12-16 deletion in the Celera assembly (Figure S2C). No
AMACR sequences with deletion at CG3 or CG10, or at both sites
have been reported in genomic databases.
We used randomly sampled genomic DNA isolated from whole
blood of 96 individuals (48 males and 48 females) from a relatively
homogeneous Caucasian population of northern German for our
study [28]. A 173 bp region encompassing all 18 CG sites within
the AMACR promoter CGI were analyzed by regular and bisulfite
sequencing (Figure 2B). The CG12-16 deletion was found to be a
sequence variant with an allele frequency of 43% in the population
(Table 3 and 4). The observed genotype frequencies conform to
the expectations of Hardy-Weinberg proportions (Table 3,
p.0.05). Between male and female samples, chi-square test for
the genotype difference and allele frequency differences are not
statistically significant (p.0.05). In contrast, in these blood DNA
samples, no other deletions or mutations were found at any of the
Table 2. Deletion hotspots of AMACR CGI and their relation to the level of AMACR expression and colon histological entity.
CG deletion Pattern Expression score Histological entity
0 1 2 3 4 Normal TA VA Well Mod. Poorly
D3 only 13 41 23 27 13 36 9.1 22 22 0.0 10
D10 only 0.0 5.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 3.6
D3 & 10 17 28 0.0 0.0 0.0 24 25 0.0 0.0 0.0 0.0
D12-16 only 32 21 53 67 66 31* 39* 33* 56 89 14*
D3 & 12-16 1.2 0.0 2.3 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0
D10 & 12-16 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
D3, 10 & 12-16 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
No changes 37 5.9 22 6.8 22 6.4 25 46 22 11 72
Samples were divided into five groups according to their AMACR expression score (Left) or into six groups according to their histologic entity (Right). Left: Deletion at
CG3 (D3 only) fluctuated as AMACR expression level went from 0 to 4; deletion at CG10 (D10 only) was a rare (#5%) event in colon cells; Notably, CG3 and 10 double-
deletions (D3 & 10, bold) were the only deletions identified in groups with low AMACR expression (score: 0–1). Frequent CG12-16 deletion (D12-16 only, bold) was
correlated with high AMACR expression (53%, 67% and 66%, respectively. Score: 2–4). The rest of deletion combinations (D3 & 12-16; D10 & 12-16; and D3, 10 & 12-16)
were not found or were at a low level (,2.5%). Right: Double-deletions at CG3 and 10 were found only in the normal and TA samples and notably absent in VA and
CCas of all grades. CG12-16 deletion was found in all the sample groups but occurred at higher frequencies in well- and moderately differentiated cancers (56% and
89%, respectively). In contrast, in the poorly differentiated cancers, the sequence of the CGI was largely unchanged (72%) with only 14% deletion of CG12-16. Mutual
exclusion of deletion at CG12-16 and double-deletion at CG3 and 10 (0%) is one of the features of the samples studied. Compared with the moderately differentiated
group that has the highest deletion rate, significant difference of CG12-16 deletion was identified in the asterisk marked groups (
*, p,0.05).
doi:10.1371/journal.pgen.1000334.t002
Table 3. The distribution of CG12-16 deletion polymorphism.
Gender
Homozygous for wild type
alleles (# case)
Heterozygous for deletion
of CG12-16 (# case)
Homozygous for deletion
of CG12-16 (# case) Allelic frequency (%)
Male 19 20 9 40
Female 13 25 10 47
Total 32 45 19 43
The 96 blood genomic DNA samples were from general individuals in a relatively homogeneous Caucasian population of northern German. Hardy-Weinberg equilibrium
test showed within the males and females of this population, the distribution of genotype frequencies follows H-W expectation (p=0.37 and 0.75, respectively); Chi-
square test showed between male and female samples, the genotypic difference (p=0.42) and the allelic difference (p=0.31) are not statistically significant. In this
population, the frequency of the CG12-16 deletion allele is 43%.
doi:10.1371/journal.pgen.1000334.t003
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and CG10.
Interestingly, although deletions/mutations at CG3 and/or
CG10 were not found by normal sequencing, bisulfite sequencing
demonstrated that the two CG sites are methylation hotspots in
blood DNA samples, exhibiting a prevalence of 16.7% and 11.1%,
respectively (Table 4). These frequencies were higher than those
observed in tissue samples in which deletion is the predominant
type of lesion at these two sites (Table 1). The fact that both single
and double deletions at CG3 and CG10 are completely absent in
blood samples but occur at frequencies between 13–30% in colon
tissue DNA indicates that they are somatic lesions.
Deletion of CG12-16 and Double-Deletion of CG3 and 10
Exert Opposite Actions on AMACR Transcription
To determine whether the in vivo deletions affect AMACR gene
transcription, we first established that the human CCa cell line
HCT 116 is a suitable model for AMACR promoter study in vitro.
These cells express AMACR transcripts, have an intact promoter
sequence with an unmethylated CGI (data not shown), and
therefore should have an intact ‘‘transcriptional machinery,’’
including transcription factors for AMACR expression. Real-time
RT-PCR showed that this cell line expresses both Sp1 and ZNF202
at significant levels. We cloned a long (1,818 bp; 21821/24) and
a short (599 bp; 2602/24) 59 AMACR promoter sequence, both
containing the newly identified CGI, into pGL3b reporter vector
(Figure 4A). The two sequences showed comparable promoter
activities in HCT 116 cells. These data suggest the localization of
core promoter elements within the 599-bp sequence (AMACR599),
which was used to derive all other mutants in this study.
To directly demonstrate that the deletion hotspots affect gene
transcription, we generated deletion and/or mutation mutants of
AMACR599 by targeting single or multiple sites (Figure 4B). Since
a previous study reported gene-regulatory activity of the CCAAT
enhancer aligned to CG5 [5], we also included deletion mutants
targeting this sequence in our study. Reporter assays performed in
HCT 116 cells showed that deletion of the CCAAT enhancer
sequence at CG5 led to a marked reduction in promoter activity
(,60%) regardless the integrity of CG3, CG10, or CG12-16
(Figure 4C). However, in the presence of an intact CCAAT
enhancer, deletion of CG12-16, in the absence or presence of
CG3, CG10, or double CG3 and 10 deletions, resulted in
augmentation of promoter activity (,100%). In contrast, deletion
of CG3 and 10, but not a single deletion of either CG3 or CG10,
caused a significant loss of promoter activity (,60%). These
findings indicate that deletion of CG12-16 and double-deletion of
CG3 and 10 exert opposite actions on AMACR transcription.
To demonstrate that these regulatory mechanisms are not limited
to CCas, we transfected these mutants into two PCa cell lines (PC-3
and LNCaP) and similar data were obtained (data not shown).
Deletion Hotspots Are Located in cis-Elements Previously
Not Known to Regulate AMACR Gene Expression
We next sought to understand how these deletions affect
AMACR gene transcription. In silico analyses suggest the localiza-
tion of Sp1 binding sites at CG3 and CG10 and a non-canonical
ZNF202 binding site within the CG12-16 region (Figure 2B).
However, it should be noted that in silico-based prediction requires
experimental confirmation since recent ChIP-chip results have
demonstrated a weak match between many consensus sequences
and in vivo binding sites for specific transcription factors (TFs)
[29,30]. Poor correlations could be due a high degree of
degeneracy for some motifs and/or the participation of other
proteins at the binding sites. A series of confirmation studies were
therefore performed to support our in silico-based predictions. We
predict that deletion at CG3 or CG10 affects one of the two
putative Sp1 binding sites, and deletion at CG12-16 impede
occupancy of a ZNF202 protein to its cis-element located between
CG12-16 (Figure 2B).
Using nuclear extracts from HCT116 cells, chromatin immu-
noprecipitation (ChIP) experiments were performed. Sp1 was
found binding to a 174-bp sequence (2234/260) that contains the
two putative Sp1-sites at CG3 and CG 10 (Figure 5A, upper panel)
but not to a 169-bp sequence (19553/19721) located in the last
exon of AMACR (Figure 5B, lower panel). Small interfering
(si)RNA-mediated Sp1 knockdown decreased AMACR mRNA
expression at the second-round of transfection (Figure 5B) but did
not reduce transcript levels of glucuronidase b (GUSB)o rcyclophilin A
(PPIA), two unrelated genes (data not shown), in HCT 116 cells.
Since there is no commercially available ZNF202 antibody for
ChIP, gel shift assays were performed to assess HCT 116 nuclear
protein binding to the putative ZNF202 binding site located within
CG12-16 of the AMACR CGI. As can be seen in Figure 6A, one
specific protein–DNA complex (arrow) was formed on the 45-bp
32P-labeled double-stranded oligonucleotide (ODN) encompassing
CG12-16 and its flanking sequences (Probe WT). The formation
of this complex could be impeded by 100-fold excess of unlabeled
WT or a 26-bp ZNF202 consensus sequence (GnT; [27]).
However, it is resistant to competition by 100-fold excess of a
45-bp mutant with the ZNF202 core sequence [31] mutated (Mut)
or a 32-bp ODN devoid of CG12-16 (Del). Interestingly, protein-
DNA complex formation patterns on labeled WT and Del were
different with notable absence of the lower band that could be
competed off by excess cold WT or GnT (Figure 6B). Finally,
ectopic expression of ZNF202 induced a dose-dependent reduc-
tion of AMACR599 promoter activity and concordant lower levels
of AMACR mRNA (Figure 6C).
In sum, these findings provide evidence in support of CG3 and
CG10 as Sp1 binding sites and CG12-16 as a ZNF202 cis-element.
Sp1 and ZNF202 appear to regulate AMACR expression in an
opposite manner.
Table 4. The distribution of deletion, mutation and methylation in AMACR promoter CGI in whole blood DNA samples.
CG site 1 2 3 4567891 01 1 1 21 31 41 51 61 7 1 8
Deletion% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 42.9 42.9 42.9 42.9 42.9 0.0 0.0
Mutation% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Methylation% 2.8 0.0 16.7 2.8 0.0 0.0 0.0 0.0 0.0 11.1 0.0 0.0 0.0 0.0 0.0 0.0 5.6 2.8
Total% 2.8 0.0 16.7 2.8 0.0 0.0 0.0 0.0 0.0 11.1 0.0 42.9 42.9 42.9 42.9 42.9 5.6 2.8
No mutation was identified in the samples. Deletion hotspot (bold) was identified only at CG12-16, whereas the methylation hotspots (bold) were identified at CG3 and
CG10.
doi:10.1371/journal.pgen.1000334.t004
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PLoS Genetics | www.plosgenetics.org 7 January 2009 | Volume 5 | Issue 1 | e1000334Figure 4. Deletion hotspots in AMACR promoter CGI are the cis-acting elements. A: Promoter assays showed that AMACR599 with the CGI in
it had promoter activity comparable to that of AMACR1818, suggesting that the 599 bp region is critical for the gene regulation. Thus, we selected
AMACR599 for further investigation. The promoter activity was normalized as relative light units. B: The location of the deletion hotspots in AMACR
promoter. Various sequence variants were compared with the wild-type promoter. A previously identified CCAAT box is illustrated. C: Compared with
the wild-type AMACR599, deletion of CCAAT enhancer element at CG5, or in combination with other deletion hotspots at CG3, 10 and 12-16,
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The main objective of this study was to elucidate the regulatory
mechanism underpinning AMACR gene expression in relation to
CCa development. We identified a novel CGI upstream the
translation start site in the proximal core promoter of AMACR.
Although aberrant methylation of promoter CGIs is a common
cause of transcriptional deregulation of genes involved in
tumorigenesis [32], we found that AMACR activation did not
occur by this mechanism during colon carcinogenesis. Instead, we
found that two non-random, mutually exclusive in vivo events,
involving a double-deletion at CG3 and 10 and the deletion of
CG12-16, play essential but opposite roles in the process.
Additionally, we discovered the differential ‘‘origins’’ of these
two in vivo deletions by comparing sequencing data from blood
DNA in a general population and those from LCM-microdissected
colon samples. The deletion of CG12-16 in the AMACR 59 CGI
was found to be a constitutional allele with a frequency of 43% in a
general population. In contrast, deletions at CG3 and/or CG10
were not observed in the blood samples indicating that these are
genetic events occurring in somatic cells of the colon.
We observed a strong positive correlation between AMACR
expression and the sequence of adenoma-carcinoma progression,
suggesting a promotional function of AMACR in colon carcino-
genesis. This postulate agrees with recent studies reporting that
siRNA-mediated knockdown of AMACR mRNA or inhibition of
the enzyme activity effectively curbed the growth of PCa cells
[3,4]. Intriguingly, both gene expression and CCa progression
were closely correlated with the status of two mutually exclusive
deletions found in the iLCM samples. Specifically, the double
CG3 and 10 deletion was found only in histologically normal
colonic glands and TAs that had negligible to absent AMACR
expression and was absent in VA or CCas of all grades that had
variable levels of AMACR expression. More important, the
simultaneous deletion of these two sites effectively negated AMACR
transactivation in HCT 116. We therefore propose that deletion at
CG3 and 10 may effectively obviate colon carcinogenesis, possibly
by impeding AMACR expression in vivo. In this regard, adenomas
harboring double-deletions of CG3 and 10 might have a low
likelihood of development to CCas; its potential diagnostic value
merit further study.
In contrast to CG3 and 10 double-deletions, deletions of CG12-
16 were highly prevalent in well- and moderately differentiated
CCas that strongly expressed AMACR. This finding is impressive
because it stands in stark contrast with the classical view that
deletions cause functional inactivation of genes. In this instance,
the CG12-16 deletion in the AMACR promoter CGI behaves like a
‘‘gain-of-function’’ deletion. When viewed in this context, the
CG12-16 deletion may be part of the sequential genetic changes
that occur in tumor suppressors, DNA repair genes, and
oncogenes during the development of CCas from adenomatous
lesions [33].
Unlike the better differentiated CCas, most poorly differentiated
cancers had a low percentage of deletions at CG12-16 and lacked
AMACR expression. These cancers also had very few other
aberrations including the double-deletion at CG3 and 10, in their
AMACR promoter CGI. Because the gene is not silenced by DNA
methylation, or by irreversible genetic events such as deletions, we
have to consider the possibility that these cancers may have a
clonal origin different from that of the better differentiated
carcinomas. Alternatively, during their evolution, these cancers
may acquire a metabolic phenotype that is independent of
AMACR overexpression.
Much could be learned about the relationship between the
CG12-16 deletion polymorphism and CCa risk by comparing the
allelic frequency of this sequence variant in blood samples (Table 3
& 4) to those found in LCM-captured histological entities of the
colon (Table 1). The overall allelic frequency of this deletion
amongst the 239 alleles from the various histological entities of the
colon was found to be ,42% (Table 1, row 1), which matches the
allele frequency observed in the blood samples is ,43%. This
suggests that there may not be additional somatic events altering
the frequency of this constitutional sequence in the colon. Yet, the
prevalence of this lesion reaches 89% in the moderately
differentiated CCas, which showed significant difference
Figure 5. Transcription factors Sp1 is involved in AMACR gene
regulation in HCT 116 cells. Putative Sp1 binding site at CG3 and 10
were identified. A: ChIP assay with Sp1 antibody targeting AMACR CGI
(Figure 2B). A PCR signal was detected in the Sp1 antibody ChIP with
genomic DNA and normal IgG-immunoprecipitated DNA as the PCR
input and negative control, respectively (Figure 5A, top panel). As a
ChIP negative control, amplification of a region in the last exon of
AMACR gene distant to the putative Sp1 sites was included in the
experiment. Only the DNA input showed the amplification (Figure 5A,
lower panel). B: siRNA-mediated Sp1 knockdown decreased the AMACR
transcript level. Real-time RT-PCR demonstrated that the first-round
siSp1 decreased the Sp1 transcript level 48% (p,0.001). With the
second-round siSp1, the Sp1 transcript level further decreased 64%
(p,0.001). In parallel, the first-round siSp1 resulted in little change in
AMACR mRNA level (p=0.66). Notably, the second-round siSp1
decreased the AMACR transcript level 53% (p=0.002). In the negative
control experiments, the same set of cDNA was used and siRNA
knockdown of Sp1 did not affect GUSB and PP1A gene expression (data
not shown).
doi:10.1371/journal.pgen.1000334.g005
significantly reduced the promoter activity (58,67%, p,0.0001, one-way analysis of variance, followed by Tukey’s HSD post hoc test). No significant
differences among the CCAAT deletion groups (p=0.014 to 1) were observed. When the CCAAT enhancer was maintained intact, the single deletion
at CG12-16 or in combination with deletion hotspots at CG3 and 10 resulted in an increase in the promoter activity by 832105% (p,0.0001) but no
significant difference among the deletion groups (p=0.060 to 1). Further, when the CCAAT enhancer was maintained and CG12-16 was intact,
deletion of either CG3 or CG10 did not change the promoter activity significantly (p=0.26 and 0.69, respectively). In contrast, double-deletion at CG3
and 10 decreased the promoter activity by 69% (p,0.001).
doi:10.1371/journal.pgen.1000334.g004
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differentiated but not the well differentiated samples. Collectively,
these data adds up to the hypothesis that individuals with the
CG12-16 deletion variant are more likely to develop CCas that are
well or moderately differentiated. Conversely, those carrying the
wild type variant may be more prone to develop poorly
differentiated CCas. Clearly, such a provocative hypothesis would
have to await a well-designed population study for confirmation.
Contributing significantly to our understanding of how AMACR is
regulated, we here provide the first evidence that deletion hotspots in
the AMACR promoter CGI correspond to cis-elements for Sp1 and
that this transcription factor regulates AMACR expression. Our data
support the regulation of AMACRbySp1,asChIPassaysshowedSp1
binding to a region of the AMACR promoter CGI containing the
predicted sites and siRNA-mediated Sp1 knockdown decreased
AMACR mRNA levels in HCT 116. Reporter assays revealed that
single deletion at either CG3 or CG10 did not affect AMACR
transcription, whereas the double-deletion significantly abrogated the
promoter activity, suggesting that the integrity of one site at either
CG3 or CG10 is sufficient to maintain the promoter activity.
In contrast, deletion of CG12-16 enhanced AMACR transcrip-
tion, signifying the likely presence of a repressor binding site in this
Figure 6. ZNF202 is involved in AMACR gene regulation in HCT 116 cells. A: The
32P labeled wild type (WT) probe corresponds to a sequence
containing CG12-16 and its flanking regions (Table 5). Gel shift assays showed a single, specific shifted band (arrow) whose signal intensity could be
impeded by co-incubation with 1006excess cold WT probe or a ZNF202 consensus sequence (GnT) but not by 1006excess mutated (Mut) or CG12-
16 deleted (Del) ODNs. The other shifted bands represent unknown protein-DNA complexes formation. B, Left: Using labeled WT as a probe three
major shifted bands were identified. Signal intensities of these bands could not be reduced by co-incubation with excess cold Del ODN that has
deletion of CG12-16. Right: Using labeled Del as probe, one major band that differs from those observed with the labeled WT was identified. Its signal
intensity was not diminished by co-incubation with excess cold WT. C: Ectopic expression of ZNF202 decreased AMACR promoter activity and mRNA
level in a dose-dependent manner. Co-transfection of the ZNF202 expression plasmid with AMACR599 (10 ng) decreased the promoter activity
(p=0.007); in parallel, ectopic expression of ZNF202 (2 mg) decreased the level of AMACR mRNA (p=0.009). The asterisks indicate a significant
difference in the group compared with the control.
doi:10.1371/journal.pgen.1000334.g006
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antibody was commercially available for the immunoprecipitation.
However, results from gel shift assays were highly suggestive of the
existence of a non-canonical ZNF202 binding site within this
sequence. Our finding that ectopic overexpression of ZNF202
reduced AMACR promoter activity lends credence to this notion.
However, we are aware of the fact that these data did not provide
the definitive evidence that the CG12-16 sequence contains a
ZNF202 cis-element, which still awaits a formal demonstration in
future investigations. It is always possible that some unknown
transcription factors other than ZNF202 could be involved in this
regulation.
Intriguingly, ZNF202 is a transcriptional repressor for genes
affecting the vascular endothelium as well as lipid metabolism.
We have examined the promoters of five other ZNF202 target
genes [27,34,35] (apoA4, apoE, lecithin cholesterol acyltransferase,
lipoprotein lipase, and phospholipid transfer protein) and did not find
deletions or other aberrations in their ZNF202 cis-element in
colon and prostate cancer cells (unpublished data). Thus, the
activation of AMACR via deletion of a ZNF202 cis-element would
be a phenomenon unique to AMACR gene regulation, if the
CG12-16 sequence was shown to house this element. Several
epidemiologic and animal studies have observed associations
between the risk of metabolic syndromes/coronary heart diseases
and the prevalence of colon adenomas/carcinomas [36–38].
Perhaps the loss of ZNF202-mediated repression of specific target
genes, including AMACR, is a common cause of these diseases.
Apropos of this view, carcinogenesis is being recognized
increasingly as a metabolic disorder characterized by a shift from
glycolysis to fatty acid utilization as the energy source fueling cell
growth [2].
Finally, deletion of the CCAAT enhancer resulted in the loss of
promoter activity regardless of the status of other elements,
indicating that CCAAT enhancers are part of the basal
transcriptional complex for AMACR. However, we did not find
alterations in this cis-element in the iLCM samples, suggesting that
such alterations do not contribute to aberrant expression of
AMACR during colon carcinogenesis.
At present, it is unclear how the deletions at in the AMACR
promoter arise. However, first, we noticed that deletion hotspots at
CG3 and CG10 are also methylation hotspots (Table 1 and
Table 4). It has been reported that methylated CG sites are
mutation hotspots [39] as suggested in Figure S3A. Second,
scrutiny of the CGI sequence revealed two 7 nt direct repeats
(Figure 2B). We postulated that forward slipped-strand mispairing
[40,41] of the repeats, may result in the CG12-16 deletion during
DNA replication (Figure S3B). If this mispairing happens, such
slippage will cause the exact 20 bp deletion found in AMACR
promoter. These proposed mechanisms speculated to be respon-
sible for these deletions will of course have to await future
experiments for corroboration.
Collectively, we identified two major types of in vivo deletions in
the AMACR promoter that appear to modulate gene expression
and may play contrasting roles in carcinogenesis. In essence, a
double-deletion at CG3 and 10 prevents AMACR overexpression
and may impede colon carcinogenesis. In contrast, carriers of
sequence variants with or without the CG12-16 deletion may have
different propensity to develop well/moderately differentiated
CCas versus the poorly differentiated cancers. Finally, our data
suggest that these deletion hotspots are cis-elements for Sp1 at
CG3 or CG10 and for ZNF202 at CG12-16. The proposed
mechanisms for AMACR promoter regulation and the deletion
hotspots provided important platforms for the further study of
AMACR gene deregulation during carcinogenesis.
Materials and Methods
Samples
Archival specimens were obtained from the Department of
Pathology at the University of Massachusetts Medical School.
Specimens from 35 cases were immunostained and microdissected
to obtain the 55 iLCM samples: 11 TAs with mild dysplasia, 8 VAs,
6 well differentiated carcinomas, 6 moderately differentiated
carcinomas, 7 poorly differentiated carcinomas, and 17 histologi-
cally normal colon tissues with 9 normal crypt and 8 apical surface
epithelial samples. For the TAs, pronounced dysplastic changes,
which often linked to positive AMACR, were uncommon. Most of
the foci had mild dysplastic changes, and we focused our study of
TAs on this type of sample. These samples were used for bisulfite
sequencing analysis. Specimens for nine additional cases were
obtained from the Pathology Department of the University of
CincinnatiMedical Centerand used toobtainnineLCMsamples of
normal epithelial, adenomatous, and carcinomatous cells for a
regular DNA sequencing for comparison with bisulfite sequencing.
Blood samples for polymorphism assay were from a relatively
homogeneous Caucasian population of northern German [28]. The
use of these samples was reviewed and approved by the respective
institutional review boards at the two institutions.
Immunohistochemistry and Laser-Captured
Microdissection
Multiple sections were cut from each case specimen. One
section was stained with hematoxylin and eosin (H&E) and used
for identification of histologic entities. The others were immuno-
stained for AMACR with the P504S antibody (Dako Cytomation,
Carpinteria, CA) and lightly counterstained with hematoxylin as
previously described [8,42]. Areas representative of the histologic
features and the overall intensity of AMACR expression found in a
given case were identified in immunostained sections. These areas
were then located in the replicate. The coverslips were then
removed, H&E-stained, and microdissected as previously de-
scribed [43].
Evaluation of AMACR Protein Expression
Each of microdissected foci was given a score (0–4) reflective of
the level of AMACR expression. When uniformly intense
immunostaining was observed in at least 95% of cells in the
section, the level of AMACR expression was designated as very
strong (score=4). If staining was less intense, not uniform
throughout the section, and in fewer than 95% of the cells, the
level of expression was designated as strong (score=3). If the
intensity of stain was weak, not uniform, and in 50% or fewer the
cells, the section was graded as medium (score=2) or weak
(score=1). Cases were scored as negative (score=0) when the
section showed no staining.
Bisulfite Sequencing and Regular DNA Sequencing
Analysis
Genomic DNA was extracted from the LCM samples by
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) with 20 mgo f
yeast tRNA added as a carrier. DNA was bisulfite-modified with
the CGenome DNA Modification Kit (Millipore, Billerica, MA).
Sequencing service was provided by Macrogen (Seoul, Korea) with
BigDye terminator used in a 96-capillary 3730xl DNA analyzer.
Bisulfite-sequencing PCR-targeting AMACR promoter CGI was
conducted by nested PCR. Primers AM-bisF1/AM-bisR1 and
AM-bisF2/AM-bisR2 (Table 5 and Figure 2) were used in the first
round and nested PCR, respectively. The targeting region was
Deletion Hotspots Regulate AMACR Promoter
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PCR was performed with platinum Taq (ABI/Invitrogen,
Carlsbad, CA) for 38 cycles with the annealing temperature at
56uC and 57uC in the first and nested PCR, respectively.
Amplified fragments were purified in 1% agarose gel, TA-cloned,
and about five colonies were picked from each sample for
sequencing. Regular sequencing of the same CGI flanking region
was performed in parallel using unmodified DNA samples and the
regular primers AM-F1/AM-R1 and AM-F2/AM-R2 (Table 5).
Proper controls were included in all experiments to ensure that the
findings were not confounded by incomplete bisulfite modification,
PCR artifact, or sequencing errors.
Polymorphism Study in AMACR Promoter
Blood genomic DNA for the polymorphism study was extracted
by DNeasy Blood & Tissue Kit. Using 50 ng genomic DNA as
template, the PCR was performed for 40 cycles in the presence of
5% DMSO by platinum Taq with PolyF/PolyR as the primers
(Table 5 and Figure 2). The annealing temperature was set at
58uC. The expected PCR product encompassing CpG sites 1–18
without CG12-16 deletion is 173 bp in length. After gel
purification, the PCR products were TA cloned and the plasmids
in colonies were directly amplified for sequencing by the Rolling
Circle Amplification Kit (GE Health Care, Piscataway, NJ). PCR
products from alleles with the deletion of CG12-16 could also be
visualized by a size difference from amplicons derived from wild
type alleles in a 3% agarose gel. To determine the prevalence of
methylation in this region of the AMACR promoter, aliquots of the
extracted genomic DNA was subjected to bisulfite sequencing.
Promoter Construction and 59- and Site-Specific
Deletions
The AMACR promoter region immediately upstream of the
translation start site was amplified from genomic DNA of
Table 5. Primers and oligonucleotides used in this study.
Assay Primer Sequence: 59R39
Bisulfite sequencing (AMACR CGI) AM-bisF1 GGTAATAGGTAGGAGTTTTAAAGGTTAGTT
AM-bisR1 AAAACTAAACAACCCTTAACCCCAACC
AM-bisF2 TTGTAATTTAAGATTTAGGAATTTAGGTTG
AM-bisR2 ACAACCTACAAAAAACCCTCCCAATC
Regular sequencing (AMACR CGI) AM-F1 CTGGGGATCGCCCTGGTACA
AM-R1 ACAGCTCCACGACCGAGATG
AM-F2 AGAGGACGGTAACAGGCAGGAG
AM-R2 AGGAAACTGAGCAGCCCTTAGC
Polymorphism study PolyF CAACCTACTGCATTTGGCACTG
PolyR CTGCAAGAAGCCCTCCCAAT
Promoter construction (AMACR) pAM-F1 ACTCGAGGTTTTGATTTGCATTTCCCTGA
pAM-R0 GAAAGCTTCCCAGTGCCCCGCTGAA
pAM-F2 ACTCGAGTTCCTAGTGTAGTCTAAACT
ZNF202 (expression) NotIZ202 TTGCGGCCGCTACAGCCGTGGAACCAGAGGA
Z202ApaI TTGGGCCCTAGGAGGTCTTTTCTGAGTGGGTCCT
ChIP (Sp1) Sp1-IPf AGCAACCTACTGCATTTGGCACTG
Sp1-IPr CTGCAAGAAGCCCTCCCAATC
ChIP negative control ChIPnegF GGCCTTTTGTCTTGGTGTTCAT
ChIPnegR CGTAGTGAGCCAACACATTTCC
Probes for gel shift assay WT TTGGGGCGCGGCGCCGCGGCTGGGGGCGTGGCGCCGGGGATTGGG
Mut TTGGGGCGCGATATTACGATTAAAAACGTGGCGCCGGGGATTGGG
Del TTGGGGCGCGGCGCCGGGGATTGGGAGGGCTT
GnT GTTGGTGGGGTGGGGGTGGGGGTGCC
Real-time RT-PCR (Sp1 and AMACR) Sp1f CCAGGCCTCCAGACCATTAACC
Sp1r GGCATCTGGGCTGTTTTCTCCT
AMf GGGCCCGTTCTGTGCTATGGT
AMr TGGGCCCAGCTGGAGTTTCTC
Real-time RT-PCR negative control GUSBf AAACGATTGCAGGGTTTCAC
GUSBr CTCTCGTCGGTGACTGTTCA
PP1Af TTCATCTGCACTGCCAAGAC
PP1Ar TCGAGTTGTCCACAGTCAGC
*Underlined: Promoter construction and ZNF202 expression, restriction sites for cloning; Gel shift assay probe WT, putative ZNF202 core sequence (MatInspector)
flanking the CG12-16 region; Mut, mutated WT probe in the putative ZNF202 core sequence with C to T and G to A substitution; GnT, ZNF202 GnT consensus sequence
in the apoAIV promoter region [27].
doi:10.1371/journal.pgen.1000334.t005
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underlined) and reverse primer pAM-R0 (HindIII site underlined)
used in PCR, the resulting 1818-bp AMACR promoter (from
21821 to 24) was cloned into luciferase reporter vector pGL3b
(Promega, Madison, WI) and designated as AMACR1818. The
promoter sequence was verified by sequencing. A 59 truncated
promoter (designated as AMACR599, from 2602 to 24) was
generated by nested PCR with PAM-F2/PAM-R0 as the primers.
Promoter site-specific deletion variants were obtained by using the
Genetailor site-directed mutagenesis kit (Invitrogen). After se-
quencing, the promoter variants were released from the cloning
vector and recloned into pGL3b.
Cell Culture, Transfection, and Promoter Luciferase Assay
All reagents used for cell cultures, including heat-inactivated
FBS, were obtained from Invitrogen. Human CCa cell lines HCT
116, SW480, SW620, and DLD-1 were obtained from the
American Type Culture Collection (Manassas, VA). The cells
were maintained in the same condition as HCT 116 cells, which
are cultured according to the provider’s recommendations. Unless
specified, 6610
4 HCT 116 cells were plated one day before
transfection in each well of the 24-well plate. The cells were
transfected with a total of 0.2 mg of DNA, including 10 ng of
cotransfected CMV promoter-driven LacZ gene (CMV-LacZ) as
the internal control. Plasmids for transfection were purified with
the EndoFree Plasmid Maxi Kit from Qiagen. Two microliters of
Plus and 1 ml of Lipofectamine (Invitrogen) were used in the
transfection according to the protocol. The promoter activity was
analyzed as previously described [44].
Chromatin Immunoprecipitation (ChIP)
The ChIP assay was performed with the EZ ChIP Kit from
Millipore according to the manufacture’s instruction. A total of
7.5 mg of anti-Sp1 rabbit polyclonal IgG (cat. no. 07-645,
Upstate/Millipore) was used in each IP. Primers Sp1-IPf/Sp1-
IPr targeting 2234 to 260 CGI (Table 5) were used in PCR with
platinum Taq in the presence of 5% DMSO with an initial
denaturation at 94uC for 1 min, followed by 36 cycles of 94uC for
30 sec, 58uC for 30 sec, and 72uC for 15 sec. As a negative control
for DNA IP, primers ChIPnegF/ChIPnegR targeting the gene’s
last exon were used in PCR (Table 5).
Real-Time RT-PCR
RNA extraction, reverse transcription, and real-time PCR,
together with the primers for GAPDH and 18S rRNA, were
described previously [44]. The tested primers used to detect
AMACR and Sp1 transcripts were AMf/AMr and Sp1f/Sp1r,
respectively (Table 5). As the siRNA control, primers for GUSB
and PP1A gene were used in the real-time RT-PCR and listed in
the Table 5. The relative level of gene expression was calculated
by the 2
2DDCt method as described in detail in our previous studies
[44,45].
Small Interfering RNA-Mediated Sp1 Knockdown
1.5610
5 HCT 116 cells were seeded at day -1 before
transfection in each well of the 6-well plate. At day 0, transfection
was performed with 5 ml of Lipofectamine 2000 (Invitrogen/ABI)
and 7.5 mlo f2 0mM siRNA per well according to the protocol.
siSp1 (ON-TARGETplus SMARTpool, cat. no. L-026959-00,
Dharmacon, Lafayette, CO) was used to knockdown Sp1
expression with Non-Targeting siRNA (cat. No. D-001210-01-
05) as the control. At day 3, the cells either were collected for real-
time RT-PCR analysis or were split at 1.5610
5 cells per well. The
second round of siRNA was performed on day 4 and analyzed on
day 7. To demonstrate the specificity of siRNA knockdown effects,
in parallel, the expression of two unrelated genes of GUSB and
PP1A were analyzed.
Ectopic Expression of Zinc Finger Protein 202 (ZNF202)
Full-length coding sequence of ZNF202 m1 transcript [27] was
amplified by primers NotIZ202 and Z202ApaI (Table 5) from
LNCaP cDNA. The sequencing-verified fragment was subcloned
into pcDNA4/His/Max A expression vector (Invitrogen). For real-
time RT-PCR, the expression plasmid was transfected into HCT
116 in the 6-well plate with the Nucleofector Kit and Nucleofector
II device from Amaxa (Gaithersburg, MD).
Gel Mobility Shift Assay
Probe sequences were shown in Table 5. Complementary
single-strand DNA oligos were annealed in 16PCR buffer
(20 mM Tris-HCl, 50 mM KCl, pH 8.4) in a water-filled heat
block. The annealing mixture was heated at 95uC for 3 min and
cooled to below 30uC in 1 hr to generate 50 mM double-strand
oligo. The double-strand oligos showed a single and stronger band
in 3% agarose gel, and located at a different position than the
single-strand oligos (photos not shown). HCT 116 cells nuclear
extract was prepared by Nuclear Extract Kit (Active Motif,
Carlsbad, CA) according to the manufacturer’s instructions. Three
mg of nuclear extract (1 ml) was used in each binding assay at 18uC
in 10 ml. The assays were carried out according to the protocol
described in the Gel Shift Assay System (Promega) with the
following modifications: Probe labeling was performed with 10 U
T4 polynucleotide kinase (New England Biolabs, Ipswich, MA)
and 2 ml[ c-
32P]ATP (3,000 Ci/mmol at 10 mCi/ml, Perkin
Elmer, Waltham, MA) in a total volume of 10 mla t3 7 uC for
20 min. Electrophoresis of DNA-protein complexes was resolved
in 6% DNA Retardation gel (Invitrogen) using 4uC 0.56 TBE
buffer at 250 V for ,35 min. Dried gels were exposed to X-ray
film at 280uC for ,1 hr and the images were captured by a
digital camera.
Genbank Accession Numbers
Five newly identified sequences of AMACR promoter variants
with deletion/mutation at CpG hotspots were deposited into the
Genbank (http://www.ncbi.nlm.nih.gov/Genbank/). The acces-
sion numbers for these variants are from EF636492 to EF636496,
which represent a CG3 deletion, a CG3 mutation, a CG10
deletion, CG3 and 10 double-deletions, and a CG12-16 deletion,
respectively. In addition, the accession number for the AMACR
promoter from the Genbank reference assembly and Celera
assembly are NT_006576.15 and NW_922562.1, respectively.
The transcript reference sequences are NM_014324.4 and
NM_203382.1 for AMACR, NM_003455 for ZNF202 m1,
NM_138473.2 for Sp1, NM_000181.2 for GUSB, and
NM_021130.3 for PP1A.
Bioinformatics Analyses
Extensive gene analyses were carried out with GeneCards (www.
genecards.org). BLAST (www.ncbi.nlm.nih.gov/BLAST/) was
used to compare the sequence against Genbank. CGI was identified
by MethPrimer at http://www.urogene.org/methprimer/
index.html. Gene exon and intron information was obtained from
Blat (http://genome.ucsc.edu/). PCR primers, except for real-time
RT-PCR negative control (Real Time Primers, Elkins Park, PA)
and bisulfite PCR, were designed by Primer3 [46] at http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. The sequencing
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Putative TF binding sites in AMACR promoter deletion hotspots
were scanned by MatInspector [31]. MatInspector utilizes tran-
scription factor knowledge base to locate putative TF binding sites
in sequence and minimize the number of false positive hits, but
requires further confirmation through wet-bench works. It defines
the ‘‘core sequence’’ (Table 5 and Figure 2B) of a putative binding
site as the consecutive highest conserved positions in the DNA
binding site.
Statistical Analyses and Hierarchical Cluster Analysis
Thehierarchicalclusteranalysiswasbasedontheaveragelinkage
principle, and the absolute number of co-occurrences of different
CG deletions was based on the similarity measure. The differences
in AMACR expression (Figure 1) in the microdissected foci were
compared among the different histologic categories using a one-way
analysis of variance (nonparametric), followed by Tukey’s HSD post
hoc test for comparisons of all classes of lesions against normal
cryptal cells. The analysis of CG12-16 deletion among the different
histologiccategories(Table2)wascarried outbySASProcGenmod
software that assuming a log link and robust standard error
estimation. The program estimates and tests differences between
groups with respect to the proportion of deletion. A generalized
linear model of binomial proportions was analyzed to detect
differences. In other experiments, a two-tailed, unpaired t-test was
performed between two groups. Except else where mentioned, the
columns with error bars in the figures represent mean695%
confidenceinterval.Forthe CG12-16deletionpolymorphismstudy,
Hardy-Weinberg equilibrium was used to test if specific disturbing
influences are introduced to the samples, and chi-square test was
used to exam genotypic and allelic differences between male and
female. In all the analyses in this paper, unless otherwise stated,
p,0.05 was considered as statistically significant.
Supporting Information
Figure S1 Cluster analyses of mutation and the overall aberra-
tions in AMACR promoter CGI. The same approach was used as
indicated in Figure3. Mutationbasicallyoccurred at CG3and 10 in
the LCM-captured colon samples, whereas the overall aberrations
of deletion, methylation and mutation were at CG3, 10, and 12-16.
Found at: doi:10.1371/journal.pgen.1000334.s001 (0.12 MB TIF)
Figure S2 Quality control of bisulfite treatment, PCR, and
sequencing. A: Representative bisulfite sequencing result with
AMACR promoter short deletion at CG12-16 as an example. No
CG compression was observed in the sequencing chromatogram.
The peaks are discrete with clean background. The Cs (highlighted
in red) in the ‘‘wild-type’’ AMACR promoter sequence were
converted to Ts, demonstrating the complete bisulfite modification
and hypomethylation of the CGI. B, Left: Bisulfite-specific PCR
with the wild-type and CG12-16 deleted AMACR promoter as the
template. The templates were cloned from AMACR promoter with
the sequence verified. W, wild-type DNA template; D: template
with CG12-16 deletion; (-): No template control. M: DNA marker.
B, Right: Multiple bisulfite PCR assays demonstrating consistent
size differences from samples carrying alleles with or without a
deletion of CG12-16. C: Both the wild-type AMACR promoter
sequence and the CG12-16 deleted sequence were identified in
human genome assembly. NT_006576.15: reference assembly;
NW_922562.1: Celera assembly.
Found at: doi:10.1371/journal.pgen.1000334.s002 (1.28 MB TIF)
Figure S3 Putative deletion mechanisms at the CG hotspots. A:
CpG methylation-mediated mutation involved in the deletion at
CG3 and 10. CG3 and 10 are the methylation hotspots.
Methylated C is the hotspot of modification or spontaneous
deamination that may result in the deletion caused by repairing
deficiency. B: Slipped-strand mispairing involved in the deletion at
CG12-16. Two direct repeats of 7 nt (bold) were located
downstream of the CG11 (underlined). Forward slippage, usually
2–3 bp within the direct repeats during DNA replication, leads to
the 20-bp deletion.
Found at: doi:10.1371/journal.pgen.1000334.s003 (0.25 MB TIF)
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